Contents lists available at ScienceDirect



Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Nonactin biosynthesis: Setting limits on what can be achieved with precursor-directed biosynthesis

Brian R. Kusche, Joshua B. Phillips, Nigel D. Priestley*

Department of Chemistry, The University of Montana, 32 Campus Drive, Missoula, MT 59812, USA

ARTICLE INFO

Article history: Received 30 October 2008 Revised 16 December 2008 Accepted 17 December 2008 Available online 30 December 2008

Keywords: Nonactin Precursor-directed Biosynthesis

ABSTRACT

Nonactin, produced by *Streptomyces griseus* ETH A7796, is a macrotetrolide assembled from nonactic acid. It is an effective inhibitor of drug efflux in multidrug resistant erythroleukemia K562 cells at sub-toxic concentrations and has been shown to possess both antibacterial and antitumor activity. As total synthesis is impractical for the generation of nonactin analogs we have studied precursor-directed biosynthesis as an alternative as it is known that nonactic acid can serve as a nonactin precursor in vivo. To determine the scope of the approach we prepared and evaluated a furan-based nonactic acid derivative, **11**. Although no new nonactin analogs were detected when **11** was administered to *S. griseus* fermentative cultures, a significant inhibition of nonactin biosynthesis was noted ($IC_{50} \sim 100 \,\mu$ M). Cell mass, nonactic acid production and the generation of other secondary metabolites in the culture were unaffected by **11** demonstrating that **11** selectively inhibited the assembly of nonactin from nonactic acid. While we were unable to generate new nonactin analogs we have discovered, however, a useful inhibitor that we can use to probe the mechanism of nonactin assembly with the ultimate goal of developing more successful precursor-directed biosynthesis transformations.

© 2008 Elsevier Ltd. All rights reserved.

Streptomyces griseus subsp. griseus ETH A7796 (DSM40695) makes a series of ionophore antibiotics known as the macrotetrolides (Fig. 1).¹ Nonactin, the prototypical macrotetrolide (**1**) is assembled from two monomers of (–)-nonactic acid and two monomers of (+)-nonactic acid assembled (+)-(–)-(+)-(–) in a head-to-tail manner into a 32-membered macrocycle. Nonactin has both antibiotic and anticancer properties² and has been shown to be an inhibitor of drug efflux in multiple drug resistant cancers.³ The natural macrotetrolide homologues produced by *S. griseus* show a wide range potency with the minimum inhibitory concentration of **1** being an order of magnitude greater than that of dinactin (**3**) against *Staphylococcus aureus* and *Mycobacterium bovis*, a difference that is related to the stability constants of their respective Na⁺ and K⁺ complexes.^{1,2,4}

Nonactin is far too hydrophobic and insufficiently soluble to be an effective therapeutic.⁵ The development of therapeutics based upon nonactin, therefore, will be dependent upon being able to make non-natural analogs in a direct and efficient manner. The total synthesis of nonactin has been achieved by a number of groups^{6–9} as has the synthesis of nonactic acid.^{10,11} The total synthesis of nonactin analogs is complicated as both enantiomers of nonactic acid, and its analogs, are required as is the sequential construction of a linear tetraester prior to a final macrolactonization reaction affording the



6 R = Me (+)-nonactic acid

* Corresponding author. Tel.: +1 406 243 6251.

Figure 1. The structures of the naturally occurring macrotetrolides and the monomer, nonactic acid.

E-mail address: nigel.priestley@umontana.edu (N.D. Priestley).

nonactin analog. This complexity does not lend itself to straightforward drug development.

Fermentative cultures of *S. griseus* can generate 6–15 g/L of macrotetrolide mixtures (>90% **1** and **2**). When nonactic acid is added to fermentative cultures of either *S. griseus*, or genetically altered strains of *S. griseus* that have been blocked in the early stages of nonactin biosynthesis, it can be readily and efficiently incorporated into nonactin.¹² These observations strongly suggest that precursor-directed biosynthesis has the potential to generate new nonactin analogs.^{13,14} As we know that a complex structure such as nonactic acid will serve as a substrate for precursor-directed biosynthesis, most straightforward nonactic acid analog that would work. To that end we completed the synthesis of the substituted furan derivative **11** (Scheme 1) and evaluated it in precursor-directed biosynthesis experiments.

Alkylation of a furan-derived anion with propylene oxide was achieved using White's method affording **8** in 66% yield after distillation.¹⁰ The secondary alcohol of **6** was protected as an acetate by reaction with acetic anhydride in pyridine to give **9** (79%).¹⁵ The furan derivative **10** was obtained by a free radical addition reaction with ethyl 2-iodopropionate, as described by Baciocchi and Muraglia, to give **10** in 11% yield.^{16,17} Saponification of **10** gave the free acid **11** (81%).¹⁸ Although the synthesis generated a mixture of diastereoisomers, the synthesis was quite short and effective and we hoped that new analogs would more likely be formed using such a mixture in a precursor-directed feeding experiment.

To assess the incorporation of compound **11** into new macrotetrolide analogs, two fermentative cultures of *S. griseus* ETH A7796 were prepared from a single vegetative culture and grown for 48 h under standard conditions.¹⁹ At 48 h after inoculation of the fermentative culture (50 mL), 56 mg of **11** (56 mg in 0.5 mL of ethanol) was added to one culture; a blank sample (0.5 mL ethanol) was added to the equivalent control culture. The cultures were allowed to grow for an additional 96 h and the macrotetrolide mixture was isolated according to standard protocols.¹⁹ Analysis of the macrotetrolide mixtures by HPLC²⁰ and LC–MS (TOF)²¹ showed an unexpected drastic reduction in macrotetrolide production in the fed culture compared to the control. Unfortunately, no likely nonactin analogs could be detected in the extract by both LC–MS and MS analysis of the complex mixture.

We decided to further evaluate the inhibitory effects of **11** on the production of nonactin to determine if adding less material might allow for the production of higher levels of nonactin in which a low incorporation of **11** might then be more evident. To this end a series of fermentative cultures were evaluated, with a range of concentrations of **11** ranging from 0.01 mM to 10 mM, together with a control culture receiving no exogenous compound.



Scheme 1. Synthesis a furan-based nonactic acid analog **11**. Reagents and conditions: (a) *n*-BuLi, -78 °C, THF then propylene oxide, 66%; (b) Ac₂O, pyridine, THF, 79%; (c) BEt₃, Fe₂(SO₄)₃, ethyl DL-2-iodopropionate, DMSO, 11%; (d) 2.5 M LiOH, MeOH, THF, 81%.

Mycelia were recovered from each culture and an approximate wet weight determined; addition of **11** had no effect upon biomass production. Macrotetrolides present in the extracts were quantified by reverse-phase HPLC.²⁰ It was determined that nonactin production was inhibited by more than 90% in fermentative cultures containing either 10 mM or 1 mM of 11. Nonactin production was at the same level as in the control in a culture containing 0.01 mM of 11; a concentration of 0.1 mM of 11 lead to an intermediate level of nonactin production. In all cases, no new macrotetrolide analogs were evident in either MS or LC-MS analyses of the extracts. In addition to showing that **11** had little effect on biomass production, each of the fermentative cultures reliably generated other secondary metabolites (phenazines) usually co-synthesized with macrotetrolides when secondary metabolism is initiated in S. griseus. Furthermore, analysis²² of the extracts demonstrated that both enantiomers of nonactic acid, the monomer precursor to nonactin, were generated in each culture irrespective of the concentration of 11 added. We have demonstrated, therefore, that while **11** does not serve as a precursor to new macrotetrolides, it is indeed a reasonably potent (IC $_{50} \sim 100 \ \mu M)$ and selective inhibitor of nonactin biosynthesis. As nonactic acid production is not perturbed, the furan derivative **11** is interfering with the assembly of nonactin from its monomeric precursors, a process that requires only the products of the nonK and nonJ type II polyketide synthaseencoding genes and the nonL CoASH-dependent ligase-encoding gene.^{23,24} The inhibition shown by **11** is distinguished from that of our earlier acetylenic analogs which likely block the formation of the monomer, nonactic acid.²⁵

While we were not successful in the developing new nonactin analogs through precursor-directed biosynthesis we have set limitations on the nonactic acid analogs that may be used; it is likely that the tetrahydrofuran ring of nonactic acid will be essential. We have discovered, however, an inhibitor that likely will be of use in our quest to determine how the macrocycle of nonactin is constructed in vivo from monomeric precursors which, in turn, will allow us to develop improved approaches for the discovery of nonactin analogs by precursor-directed biosynthesis.

Acknowledgment

Financial support of this work from the NIH (CA77347) is gratefully acknowledged.

References and notes

- Keller-Schierlein, W.; Gerlach, H. Fortschritted. Chem. Org. Naturstoffe 1968, 26, 161.
- Meyers, E.; Pansy, F. E.; Perlman, D.; Smith, D. A.; Weisenborn, F. L. J. Antibiot. 1965, 18, 128.
- Borrel, M. N.; Pereira, E.; Fiallo, M.; Garnier-Suillerot, A. Eur. J. Biochem. 1994, 223, 125.
- 4. Izatt, R. M.; Bradshaw, S. A.; Nielsen, S. A.; Lamb, J. D.; Christensen, J. J.; Sen, D. *Chem. Rev.* **1985**, 85, 271.
- 5. Lipinski, C. A. J. Pharm. Toxicol. Meth. 2000, 44, 239.
- 6. Lee, J. Y. K.; Byeang, H. Tetrahedron Lett. 1996, 52, 571.
- 7. Lee, J. Y. K.; Byeang, H. Tetrahedron Lett. **1995**, 36, 3364.
- 8. Fleming, I. G.; Sunil, K. J. Chem. Soc., Perkin Trans. 1 1998, 17, 2733.
- 9. Fleming, I. G.; Sunil, K. J. Chem. Soc., Chem. Commun. 1994, 19, 2287.
- 10. Arco, M. J.; Trammell, M. H.; White, J. D. J. Organic Chem. 1976, 43, 479.
- 11. Bartlett, P. A. M.; James, D.; Ottow, Eckhard J. Am. Chem. Soc. 1984, 106, 5304.
- 12. Woo, A. J.; Strohl, W. R.; Priestley, N. D. Antimicrob. Agents Chemother. 1997, 43, 1662.
- Ritacco, F.; Graziani, E.; Summers, M.; Zabriskie, T.; Yu, K.; Bernan, V.; Carter, G.; Greenstein, M. Appl. Environ. Microbiol. 2005, 71, 1971.
- 14. Jacobsen, J.; Hutchinson, C. R.; Cane, D. E.; Khosla, C. Science 1997, 277, 367.
- 15. 1-(Furan-2-yl)propan-2-yl acetate (9). Acetic anhydride (12.8 mL, 135 mmol) and then pyridine (18.4 mL, 225 mmol) were added to a solution of 8 (5.7 g, 45 mmol) in THF (15 mL). The resulting solution was stirred at room temperature for 2 h after which the reaction was quenched by the addition of water (100 mL). The resulting mixture was extracted with ethyl acetate (3× 100 mL) and the organic phases were recovered, combined and washed with water (50 mL), aqueous

saturated copper sulfate (2× 100 mL) and finally ammonium chloride solution (2× 100 mL). The extracts were dried (Na₂SO₄), filtered and concentrated to a residue which was purified by distillation (96 °C, 24 mmHg) to give (**9**) (6.0 g, 79%). R_f = 0.50 (10% ethyl acetate/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.24 (s, 1H), 6.21 (s, 1H), 5.99 (s, 1H), 5.08 (sextet, J = 127, 6.4 Hz, 1H), 2.85 (dd, J = 15.1, 6.4 Hz, 1H), 2.75 (dd, J = 15.1, 6.4 Hz, 1H), 1.93 (s, 3H) and 1.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 17.01, 151.4, 141.2, 110.0, 106.7, 69.0, 34.2, 20.9 and 19.3; IR (ATR) 2982, 2937, 1736, 1372, and 1237 cm⁻¹.

- 16. Baciocchi, E.; Muraglia, E. Tetrahedron Lett. 1993, 34, 5015.
- Ethyl 2-(5-(2-acetoxypropyl)furan-2-yl)propanoate (10). Triethylborane (1.0 M, 17 182 mL, 182 mmol) was added to a suspension of 9 (30.6 g, 182 mmol), ethyl DL-2-iodopropionate (41.5 g, 182 mmol) and ferric sulfate hydrate (72.8 g, 182 mmol) in DMSO (250 mL). After 45 min of vigorous stirring at room temperature while open to the atmosphere, a second addition of triethylborane (1.0 M, 182 mL, 182 mmol) was added to the suspension and the suspension was allowed to stir vigorously for an additional 45 min. Brine (200 mL) was then added and the resultant solution was extracted with Et_2O (3× 300 mL). The combined organic phases were dried (Na₂SO₄), filtered and concentrated under vacuum to give an oil. The crude oil was purified by flash chromatography (1:4 EtOAc/hexanes) to give 10 (5.34 g, 11%) as a yelloworange oil. ¹H NMR (400 MHz, CDCl₃) δ 6.01 (d, J = 3.3 Hz, 1H). 5.95 (d, J = 2.9 Hz, 1H), 5.06 (sext, J = 12.8, 6.6, 6.2 Hz, 1H), 4.10 (q, J = 14.3, 7.3, 7.0, 2H), 3.69 (q, J = 7.3 Hz, 1H), 2.73 (dd, J = 15, 6.2 Hz, 1H), 2.73 (dd, J = 15, 6.2 Hz, 1H), 1.96 (s, 3H), 1.43 (d, J = 7.3 Hz, 3H), 1.21–1.17 (m, 6H); 13 C NMR (100 MHz, CDCl₃) δ 172.5, 170.3, 152.1, 150.7, 107.6, 106.4, 69.2, 60.8, 39.4, 34.3, 21.1, 19.4, 15.6 and 14.0; IR (ATR) 2983, 2940, and 1733 cm⁻¹; ESI-TOF-HRMS *m*/*z* calcd for C14H20O5H+: 269.1398; found 269.1389.
- 2-(5-(2-Hydroxypropyl)/furan-2-yl)propanoic acid (11). A solution of 10 (2.20 g, 8.2 mmol) in 40 mL of 2.5 M LiOH/MeOH/THF (1:2:3) was allowed to stir at room temperature for 1.5 h. The reaction was acidified to pH 2 by the addition of HCl (1.0 M), extracted with EtOAc (3× 100 mL), dried (Na₂SO₄), filtered and

concentrated. The crude product was purified by chromatography on silica gel (97:2.5:0.5 EtOAc/MeOH/AcOH) to give **11** (1.32 g, 81.0%) as a clear yellow oil. $R_f = 0.54$ (99:1 EtOAc/TFA); ¹H NMR (400 MHz, CDCl₃) δ 7.40 (s, 2H), 6.05 (d, 1H, *J* = 3.3), 5.98 (d, 1H, *J* = 3.3), 4.02 (sextet, *J* = 12.4, 6.2, 2H), 3.73 (q, 1H, *J* = 7.3), 2.68 (d, *J* = 6.2, 2H), 1.46 (d, *J* = 7.3, 3H) and 1.15 (d, *J* = 6.2, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 177.3, 151.9, 151.6, 107.6, 106.8, 66.8, 39.1, 37.4, 22.2 and 15.3; IR (ATR) 3625–2375, 2973, 2922 and 1712 cm⁻¹; ESI–TOF–HRMS *m*/*z* calcd for C₁₀H₁₄Q₄H^{*}: 199.0970; found 199.0971.

- Ashworth, D. M.; Clark, C. A.; Robinson, J. A. J. Chem. Soc., Perkin Trans. 1 1989, 1461.
- 20. HPLC resolution and quantification of macrotetrolide mixtures was accomplished using a Varian microsorb-mv 100-5 250×4.6 mm C-18 column with an isocratic mobile phase of acetonitrile-water (86:14) containing 0.1% trifluoroacetic acid at a flow rate of 1 mL/min. Macrotetrolide elution was monitored by measuring the absorbance of the eluate at 215 nm. Under these conditions the macrotetrolide retention times were: nonactin, 7.50 min; monactin, 8.75 min; dinactin, 10.50 min; trinactin, 13.00 min and tetranactin, 16.33 min.
- 21. Cox, J. E.; Priestley, N. D. J. Am. Chem. Soc. 2005, 127, 7976.
- 22. The culture broth was acidified to pH 1–2 with 6 M HCl and then extracted with EtOAc. The crude extracts were analyzed by TLC (95:4:1, EtOAc/MeOH/ AcOH) and stained with anisaldehyde. The crude extracts containing nonactic and homononactic acids were also esterified by dissolving in 5% H₂SO₄ in methanol and then heating at 65 °C for 1 h. The methyl nonactate and methyl homononactate that were produced were isolated by chromatography on silica gel (50:50 EtOAc/hexanes). Additional characterization of methyl nonactate and methyl homononactate was achieved by gas chromatography.
- Walczak, K. J.; Woo, A. J.; Strohl, W. R.; Priestley, N. D. *FEMS Lett.* **2000**, *183*, 171.
 Kwon, H.-J.; Smith, W. C.; Scharon, J.; Hwang, S. H.; Kurth, M. J.; Shen, B. *Science* **2002**, *297*, 1327.
- 25. Priestley, N. D.; Earle, M. Bioorg. Med. Chem. Lett. 1997, 7, 2187.